Core Points - The company, 信铭生命科技 (00474), received a demand letter from a commercial bank in Hong Kong on April 23, 2025, requesting repayment of a total debt amounting to approximately HKD 352 million [1] - As of the date of the announcement, the company has fully repaid all outstanding debts [1]

Core Viewpoint - 信铭生命科技 has received a demand letter from a commercial bank in Hong Kong, requesting repayment of a total debt amounting to approximately HKD 352 million. As of the announcement date, the company has fully repaid all outstanding debts [1]. Group 1 - 信铭生命科技 received a demand letter for debt repayment from a Hong Kong commercial bank [1] - The total debt amount requested for repayment is approximately HKD 352 million [1] - The company has fully repaid all outstanding debts as of the announcement date [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 自願公告 全數償還香港一間商業銀行之未償還貸款 本 公 告 由 信 銘 生 命 科 技 集 團 有 限 公 司（「本公司」，連 同 其 附 屬 公 司 統 稱「本 集 團」）自 願 作 出。 Aceso Life Science Group Limited 信銘生命科技集團有限公司 茲 提 述 本 公 司 日 期 為 二 零 二 五 年 四 月 二 十 三 日 之 公 告（「該公告」），內 容 有關本公司於二零二五年四月二十三日收到一封來自香港一間商業銀 行 之 催 款 函，要 求 償 付 總 額 約 為352百 萬 港 元 之 債 務。除 另 有 說 明 外，本 公 告 所 用 詞 彙 與 該 公 告 所 界 定 者 具 有 相 同 涵 義。 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） （股份代號：00474） 本公司欣然宣佈， ...

Core Viewpoint - Recent stock transfer activities and refinancing arrangements indicate significant financial maneuvers by the company, reflecting its strategic focus on capital management and operational funding [1] Group 1: Stock Transfer Activities - On October 9, shareholders of 信铭生命科技 (00474) transferred shares from Haitong International Securities to Imagi Brokerage Limited, with a transfer value of HKD 124 million, accounting for 26.56% of the total [1] - On October 8, another transfer occurred, moving shares valued at HKD 67.98 million from Haitong International Securities to Imagi Brokerage Limited, representing 13.95% of the total [1] Group 2: Refinancing Arrangements - The company announced a refinancing arrangement related to a 2018 financing agreement, with all conditions for the 2025 loan agreement met and completed on September 26, 2025 [1] - The total financing provided amounts to approximately GBP 87.3 million, of which about GBP 70.3 million has been withdrawn to fully repay UK loans and associated transaction costs [1] - The remaining GBP 17 million is earmarked for capital expenditures on UK properties over the next one to two years [1]

Group 1 - The core point of the article highlights significant shareholder activity in Ximing Life Technology, with a total of HKD 1.24 billion worth of shares transferred to lmagi Brokerage Limited on October 9, representing 26.56% of the company's shares [1] - On October 8, another transfer occurred, with shares worth HKD 67.98 million moved from Haitong International Securities to lmagi Brokerage Limited, accounting for 13.95% of the shares [1] - The company announced a refinancing arrangement related to a 2018 financing agreement, with all conditions for a loan agreement due in 2025 met and completed on September 26, 2025 [1] Group 2 - Following the completion of the refinancing, the company secured a total financing amount of approximately GBP 87.3 million, with GBP 70.3 million withdrawn for repaying UK loans and associated transaction costs [1] - The remaining GBP 17 million is earmarked for capital expenditures on UK properties over the next one to two years [1]

Core Insights - The recent transfer of shares in Sinomax Life Technology (00474) from Haitong International Securities to lmagi Brokerage Limited amounts to a market value of HKD 67.9825 million, representing 13.95% of the company [1] Financing and Capital Expenditure - Sinomax Life Technology announced a refinancing arrangement related to a 2018 financing agreement, with all conditions for the 2025 loan agreement met and completed on September 26, 2025 [1] - The total financing provided amounts to approximately GBP 87.3 million, with GBP 70.3 million withdrawn for the repayment of UK loans and associated transaction costs [1] - The remaining GBP 17 million will be allocated for capital expenditures on UK properties over the next one to two years, including major renovation projects aimed at enhancing rental income and capital value [1]

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 信銘生命科技集團有限公司 (於開曼群島註冊成立的有限公司) 呈交日期: 2025年10月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00474 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | 50,000,000,000 | | HKD | 0.01 | HKD | | 500,000,000 | | 增加 / 減少 (-) | | | | | | HKD | | | | 本月底結存 | | | 50,000,000,000 | HKD | | 0.01 HKD | | 500,000,000 ...

（ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） （股份代號：00474） 季度進展公告 茲 提 述 信 銘 生 命 科 技 集 團 有 限 公 司（「本公司」，連 同 其 附 屬 公 司 統 稱「本 集 團」）於 二零二五年七月三十日 刊 發 之截至二零二五年三月三十一日 止 年 度 之 年 報（「年 報」）。本 公 告 旨 在 提 供 本 公 司 就 解 決 持 續 經 營 問 題 所 取 得 的 最 新 季 度 進 展。除 另 有 界 定 者 外，本 公 告 所 用 之 詞 彙 與 年 報 所 界 定 者 具 有 相 同 涵 義。 Aceso Life Science Group Limited 信銘生命科技集團有限公司 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不就因本公告全部或任何部份內容而產生或因倚賴該等內容而引致之 任 何 損 失 承 擔 任 何 責 任。 誠 如 年 報 所 披 露，本 公 司 核 數 師 未 對 本公司 截至二零二五年三月 三 十 ...

Core Viewpoint - The company has successfully completed a refinancing arrangement related to a 2018 financing agreement, securing a total financing amount of approximately £87.3 million [1] Financing Details - All conditions precedent under the 2025 loan agreement have been met, and the transaction was completed on September 26, 2025 [1] - Approximately £70.3 million has been drawn today to fully repay UK loans and related transaction costs [1] - The remaining £17 million will be allocated for capital expenditures on UK properties over the next one to two years [1] Future Plans - The company plans to undertake a major renovation project for its UK properties, which includes upgrading key facilities and amenities [1] - The aim of the renovation is to enhance rental income and capital value of the UK properties [1]

Core Insights - The company, 信铭生命科技 (00474), announced a refinancing arrangement related to a 2018 financing agreement, with all conditions for the 2025 loan agreement met and completed on September 26, 2025 [1] Financing Details - The total financing amount provided to the company is approximately £87.3 million, with about £70.3 million withdrawn today to fully repay UK loans and related transaction costs [1] - The remaining £17 million will be allocated for capital expenditures on UK properties over the next one to two years [1] Future Plans - The company plans to undertake a major renovation project for its UK properties, including upgrades to key facilities and amenities, aimed at enhancing rental income and capital value [1]